Huiwen Luan

Huiwen Luan

Auto-generated profile, based on publicly available information

Huiwen Luan

Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YLYifan Liu
Yifan Liu
HWHongying Wang
Hongying Wang
XZXinyu Zhao
Xinyu Zhao
JZJiashen Zhang
Jiashen Zhang
ZZZhiling Zhao
Zhiling Zhao
ZLZunling Li
Zunling Li
Immune checkpoints modulate the immune response and represent important immunotherapy targets for cancer treatment. However, as many tumors are resistant to current immune checkpoint inhibitors, the discovery of novel immune checkpoints could facilitate the development of additional immunotherapeutic strategies to improve patient responses. Here, we identified increased expression of the adhesion molecule immunoglobulin superfamily member 9 (IGSF9) in tumor cells and tumor-infiltrating immune cells across multiple cancer types. IGSF9 overexpression or knockout in tumor cells did not alter cell proliferation in vitro or tumor growth in immunocompromised mice. Alternatively, IGSF9 deficient tumor cells lost the ability to suppress T-cell proliferation and exhibited reduced growth in immunocompetent mice. Similarly, growth of tumor cells was reduced in IGSF9 knockout syngeneic and humanized mice, accompanied by increased tumor-infiltrating T cells. Mechanistically, the extracellular domain (ECD) of IGSF9 bound to T cells and inhibited their proliferation and activation, and the tumor-promoting effect of IGSF9 ECD was reversed by CD3+ T-cell depletion. Anti-IGSF9 antibody treatment inhibited tumor growth and enhanced the antitumor efficacy of anti-programmed cell death protein 1 immunotherapy. Single-cell RNA sequencing revealed tumor microenvironment remodeling from tumor promoting to tumor suppressive following anti-IGSF9 treatment. Together, these results indicate that IGSF9 promotes tumor immune evasion and is a candidate immune checkpoint target. Significance: IGSF9 is an immune checkpoint regulator that suppresses T-cell activation in cancer and can be targeted to stimulate antitumor immunity and inhibit tumor growth.

14 January 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
JZJiasheng Zhang
Jiasheng Zhang
XMXianhui Meng
Xianhui Meng
XZXinyu Zhao
Xinyu Zhao
HLHuiwen Luan
Huiwen Luan
FLFangmin Li
Fangmin Li
ZLZunling Li
Zunling Li
Background: IGSF9, immunoglobulin superfamily member 9, has been reported to inhibit T cell proliferation and activation, thereby promoting tumor immune escape. Tumor-associated macrophages (TAMs), the most abundant tumor-infiltrating immune cells, play a crucial role in forming the immunosuppressive tumor microenvironment. We find that IGSF9 strongly binds to TAMs, however, how it affects TAMs function remains unreported. Methods: The spatial transcriptomics dataset (GSE189487) was analyzed to clarify the relationship among IGSF9, senescent TAMs, and T cells. RNA-seq revealed differentially expressed genes. Flow cytometry was employed to assess the binding of IGSF9-ECD proteins to macrophages. Macrophage-educated by IGSF9 were co-cultured with T cells, and the phagocytosis was observed. Membrane-system yeast two-hybrid screening, GST pull-down, and co-IP were used to identify the binding partner of IGSF9. Cellular senescence markers and the senescence-associated secretory phenotype (SASP) were assessed by flow cytometry and immunofluorescence. LL/2-control or LL/2- Igsf9 cells were injected into C57BL/6, NSG, and monocytes-depleted C57BL/6 mice. Similarly, MC38- OVA -control or MC38-OVA-Igsf9 cells were inoculated into OT-II mice. Finally, anti-IGSF9 and its LALA-PG-mutant variant were administered to C57BL/6 mice to monitor tumor growth and SASP expression. Results: The spatial transcriptomics dataset (GSE189487) revealed that the level of IGSF9 in tumor cells was positively correlated with the senescence of TAMs, and RNA-seq revealed the differentially expressed genes which were related to senescence. Macrophage educated by IGSF9 exhibited distinct senescence phenotypes and immunosuppressive features, and IGSF9 bound to TMUB1 to activate the IL-6/STAT3 signal pathway to trigger the above phenotype. In vivo data showed that IGSF9 could induce TAM senescence, leading to inhibition of T cell activity and formation of an immunosuppressive microenvironment, then promoting tumor immune escape. Treatment with anti-IGSF9, including the LALAPG-mutant variant that reduces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, mitigated TAM senescence and immunosuppression, activated T cells, and suppressed tumor growth. Conclusions: TMUB1 as a binding protein of IGSF9 is first discovered, and TAMs educated by IGSF9 exhibit senescent and suppressive phenotype to orchestrate an inhibitory tumor microenvironment, which can be reversed by anti-IGSF9 to suppress tumor progression.

16 September 2024
Verified
Other
Open access
PDF file
YLYifan Liu
Yifan Liu
HWHongying Wang
Hongying Wang
XZXinyu Zhao
Xinyu Zhao
JZJiashen Zhang
Jiashen Zhang
ZZZhiling Zhao
Zhiling Zhao
ZLZunling Li
Zunling Li
Anti-IGSF9 regained the activation of T cells.

16 September 2024
Verified
Other
Open access
PDF file
YLYifan Liu
Yifan Liu
HWHongying Wang
Hongying Wang
XZXinyu Zhao
Xinyu Zhao
JZJiashen Zhang
Jiashen Zhang
ZZZhiling Zhao
Zhiling Zhao
ZLZunling Li
Zunling Li
IGSF9 itself did not affect tumor cell proliferation.

24 November 2025
Verified
Other
Open access
YLYifan Liu
Yifan Liu
HWHongying Wang
Hongying Wang
XZXinyu Zhao
Xinyu Zhao
JZJiashen Zhang
Jiashen Zhang
ZZZhiling Zhao
Zhiling Zhao
ZLZunling Li
Zunling Li
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.

24 November 2025
Verified
Other
Open access
YLYifan Liu
Yifan Liu
HWHongying Wang
Hongying Wang
XZXinyu Zhao
Xinyu Zhao
JZJiashen Zhang
Jiashen Zhang
ZZZhiling Zhao
Zhiling Zhao
ZLZunling Li
Zunling Li
Supplementary material and methods and Supplementary tables